• A placebo-controlled, double-blind multicenter trial was conducted in 123 patients with severe hypertension to examine the efficacy and safety of intravenously administered nicardipine hydrochloride in controlling blood pressure. Seventy-three patients were initially randomized to receive nicardipine treatment. This group had an initial blood pressure of 213±3/126±2 mm Hg. Sixty-seven patients achieved the therapeutic goal (diastolic blood pressure 95 mm Hg; systolic blood pressure ≤160 mm Hg). Fifty patients were randomized to receive placebo solution. Blood pressure in these patients was 216±3/125±2 mm Hg. No patient in this group achieved the therapeutic goal during the "blinded" portion of the study. Forty-four of 49 patients who did not respond to placebo administration responded to subsequent treatment with nicardipine. Patients with end-organ damage were included in the study. These included patients with left ventricular hypertrophy, retinopathy, and renal insufficiency. Patients with and without end-organ damage responded equally well to nicardipine treatment. Serious adverse experiences were infrequent, the most common adverse reaction being headache in 24% of the patients studied.
(Arch Intern Med. 1989;149:2662-2669)
Wallin JD, Fletcher E, Ram CVS, Cook ME, Cheung DG, MacCarthy EP, Townsend R, Saunders E, Davis WR, Langford HG, DeVault G, Flamenbaum W, Ellrodt G, Hamilton B, Frank S, Frishman W. Intravenous Nicardipine for the Treatment of Severe HypertensionA Double-blind, Placebo-Controlled Multicenter Trial. Arch Intern Med. 1989;149(12):2662-2669. doi:10.1001/archinte.1989.00390120034008